We are live on ! Find out more
IH

iHuman

8 hedge funds and large institutions have $7.97M invested in iHuman in 2023 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 4 increasing their positions, 1 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

300% more repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 1

100% more first-time investments, than exits

New positions opened: 2 | Existing positions closed: 1

14% more funds holding

Funds holding: 78 (+1)

2% more capital invested

Capital invested by funds: $7.8M → $7.97M (+$176K)

0.02% more ownership

Funds ownership: 4.99%5% (+0.02%)

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

Holders
8
Holders Change
+1
Holders Change %
+14.29%
% of All Funds
0.13%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.02%
New
2
Increased
4
Reduced
1
Closed
1
Calls
Puts
Net Calls
Net Calls Change

IH Hedge Fund Activity: Q3 2023 in Review

8 of the 6,310 institutional investors tracked by Wall St. Rank reported a position in iHuman (IH) for Q3 2023, worth a combined $7.97M — up 2.3% from $7.8M a quarter earlier.

Buyers outnumbered sellers: 2 funds opened new IH positions and 1 closed out — a net gain of 1 holder — while 4 added to existing stakes and 1 trimmed.

The largest buyer was Citadel Advisors, adding an estimated $12.8K. The largest seller was Renaissance Technologies, cutting an estimated $11.5K.

  • 8 institutional investors held iHuman (IH) as of Q3 2023, up from 7 in Q2 2023.
  • Funds reported $7.97M of iHuman stock for Q3 2023, up 2.3% quarter-over-quarter.
  • 2 funds opened new iHuman positions in Q3 2023 and 1 closed out, a net change of +1 holder.
  • The largest iHuman buyer in Q3 2023 was Citadel Advisors, an estimated $12.8K added.
  • The largest iHuman seller in Q3 2023 was Renaissance Technologies, an estimated $11.5K sold.

Based on aggregated 13F filings for Q3 2023.